Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P01148
UPID:
GON1_HUMAN
Alternative names:
Progonadoliberin I
Alternative UPACC:
P01148; A0AVP0
Background:
Progonadoliberin-1, also known as Progonadoliberin I, plays a crucial role in human physiology by stimulating the secretion of gonadotropins, including luteinizing and follicle-stimulating hormones. These hormones are pivotal for reproductive health, influencing both the male and female reproductive systems.
Therapeutic significance:
The protein is directly linked to Hypogonadotropic hypogonadism 12 with or without anosmia, a condition marked by delayed or absent sexual maturation due to low gonadotropin levels. Understanding Progonadoliberin-1's function could lead to novel treatments for this disorder, enhancing reproductive health and quality of life for affected individuals.